Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual

Biochemical Pharmacology

Volumn 41, Issue 9, 1991, Pages 1351-1360

  Marshall, Raymond S ^a   Paterson, Malcolm C ^b   Rauth, A Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; PORFIROMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CELL LINE; CELL SURVIVAL; CHILD; DRUG RESISTANCE; FEMALE; GLUTATHIONE; HUMAN; KINETICS; MITOMYCIN; MITOMYCINS; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; OXYGEN; PORFIROMYCIN; PRECIPITIN TESTS; QUINONE REDUCTASES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0026032132     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(91)90108-H     Document Type: Article

References (53)

1. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer
2. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C
3. Hypoxic cells as specific drug targets for chemotherapy
4. Therapeutic attack of hypoxic cells of solid tumors: Presidential address
5. Effect of the Superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics
6. DNA interstand cross-link and free radical formation in a human multidrug-resislant cell line from mitomycin C and its analogues
7. Modilication of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant
8. Effects of caffeine on L-cells exposed to mitomycin C
9. pH Dependence of mitomycin C-induced cross-linking activity in EMTA tumor cells
10. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro
11. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells hv dicoumarol in vitro
12. Modilication of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells
13. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions
14. Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo
15. Human cancer-prone disorders, abnormal carcinogen response and defective DNA metabolism
16. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells
17. Metabolic activation of mitomycin C by liver microsomes and nuclei
18. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
19. Effects of glutathione and ethylxanthate on mitomycin C activation by isolated rat hepatic or EMT6 mouse mammary tumor nuclei
20. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation
21. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells
22. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Application to mammalian blood and other tissues
23. Role of glutathione in the hypoxic cell cytotoxicity of misonidazole
24. DT-diaphorase
25. Increase of NAD(P)H:quinone reductase by dietary antioxidants: Possible role in protection against carcinogens and toxicity
26. Purification and properties of NAD(P)H-cytochrome P-450 reductase
27. Rat liver DT-diaphorase: Regulation of functional mRNA levels by 3-methylcholanthrene, trans-stilbene oxide, and phenobarbital
28. Detection of specific sequences among DNA fragments separated by gel electrophoresis
29. Complementation of the DNA-repair defect in a CHO mutant by human DNA that lacks highly abundant repetitive sequences
30. Rat liver NAD(P)H:quinone reductase: Construction of a quinone reductase cDNA clone and regulation of quinone reductase mRNA by 3-methylcholanthrene in persistent hepatocyte nodules induced by chemical carcinogens
31. Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells
32. Human dioxin-inducible cytosolic NAD(P)H: menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16
33. Bioactivation as a model for drug design: Bioreductive alkylation
34. Electrochemical reductive activation of mitomycin C
35. Role of NAD(P)H:cytochrome c reductase and DT-diaphorascin the biotransformation of mitomycin C
36. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NAD(P)H-cytochrome P-450 reductase and xanthine oxidase
37. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells
38. Mechanisms of cytotoxicity associated with two electron reduction of 2,5-diaziridinyl-3,6-bis(carboethoxyam-ino)-1.4-benzoquinone (AZQ) in human colon carcinoma cells
39. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
40. Preclinical studies of porfiromycin as an adjunct to radiotherapy
41. Alkylating activity of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds
42. Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally “alkylating” antibiotics
43. Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation
44. DT diaphorase II Relation to respiratory chain of intact mitochondria
45. vivo
46. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents
47. Increased sensitivity of quinone resistant cells to mitomycin C
48. Metabolism of mitomycin C (MC) by DT-diaphorase (DTD) and its role in MC-induced toxicity in human colon carcinoma cells
49. Relationship between the antioxidant enzyme DT-diaphorase and tumor response to mitomycin C treatment
50. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H (quinone-acceptor)oxidoreductase
51. 1-450 in the induction of NAD(P)H:quinone reductase in a murine hepatoma line and its mutant
52. Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions